Logo image of SILO

SILO PHARMA INC (SILO) Stock Fundamental Analysis

NASDAQ:SILO - Nasdaq - US82711P2011 - Common Stock - Currency: USD

0.8149  0 (0%)

Fundamental Rating

3

SILO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 563 industry peers in the Biotechnology industry. While SILO seems to be doing ok healthwise, there are quite some concerns on its profitability. SILO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SILO had negative earnings in the past year.
SILO had a negative operating cash flow in the past year.
SILO had negative earnings in 4 of the past 5 years.
In the past 5 years SILO always reported negative operating cash flow.
SILO Yearly Net Income VS EBIT VS OCF VS FCFSILO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of -59.27%, SILO is doing worse than 60.21% of the companies in the same industry.
With a Return On Equity value of -87.26%, SILO perfoms like the industry average, outperforming 49.38% of the companies in the same industry.
Industry RankSector Rank
ROA -59.27%
ROE -87.26%
ROIC N/A
ROA(3y)-46.88%
ROA(5y)-66.86%
ROE(3y)-61.66%
ROE(5y)-80.07%
ROIC(3y)N/A
ROIC(5y)N/A
SILO Yearly ROA, ROE, ROICSILO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

Looking at the Gross Margin, with a value of 92.22%, SILO belongs to the top of the industry, outperforming 92.54% of the companies in the same industry.
In the last couple of years the Gross Margin of SILO has grown nicely.
The Profit Margin and Operating Margin are not available for SILO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.76%
GM growth 5Y29.76%
SILO Yearly Profit, Operating, Gross MarginsSILO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

SILO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SILO has been increased compared to 1 year ago.
The number of shares outstanding for SILO has been increased compared to 5 years ago.
There is no outstanding debt for SILO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SILO Yearly Shares OutstandingSILO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
SILO Yearly Total Debt VS Total AssetsSILO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

SILO has an Altman-Z score of -3.16. This is a bad value and indicates that SILO is not financially healthy and even has some risk of bankruptcy.
SILO has a Altman-Z score of -3.16. This is comparable to the rest of the industry: SILO outperforms 49.20% of its industry peers.
SILO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.16
ROIC/WACCN/A
WACC9.98%
SILO Yearly LT Debt VS Equity VS FCFSILO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

SILO has a Current Ratio of 4.29. This indicates that SILO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SILO (4.29) is comparable to the rest of the industry.
SILO has a Quick Ratio of 4.29. This indicates that SILO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.29, SILO is in line with its industry, outperforming 51.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.29
Quick Ratio 4.29
SILO Yearly Current Assets VS Current LiabilitesSILO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

SILO shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.16%.
Looking at the last year, SILO shows a decrease in Revenue. The Revenue has decreased by -7.69% in the last year.
SILO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.51% yearly.
EPS 1Y (TTM)1.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.42%
Revenue 1Y (TTM)-7.69%
Revenue growth 3Y0.99%
Revenue growth 5Y12.51%
Sales Q2Q%-0.17%

3.2 Future

Based on estimates for the next years, SILO will show a very negative growth in Earnings Per Share. The EPS will decrease by -21.62% on average per year.
Based on estimates for the next years, SILO will show a decrease in Revenue. The Revenue will decrease by 0.00% on average per year.
EPS Next Y-25%
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%
EPS Next 5Y-21.62%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y0%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SILO Yearly Revenue VS EstimatesSILO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
SILO Yearly EPS VS EstimatesSILO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2 3 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SILO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SILO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SILO Price Earnings VS Forward Price EarningsSILO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SILO Per share dataSILO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A cheap valuation may be justified as SILO's earnings are expected to decrease with -25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SILO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SILO PHARMA INC

NASDAQ:SILO (5/9/2025, 3:50:00 PM)

0.8149

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25 2025-03-25/amc
Earnings (Next)05-12 2025-05-12
Inst Owners4.09%
Inst Owner Change10.9%
Ins Owners4.3%
Ins Owner Change3.89%
Market Cap3.65M
Analysts82.86
Price Target10.2 (1151.69%)
Short Float %3.03%
Short Ratio1.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 50.7
P/FCF N/A
P/OCF N/A
P/B 0.73
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS0.02
BVpS1.12
TBVpS1.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.27%
ROE -87.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.22%
FCFM N/A
ROA(3y)-46.88%
ROA(5y)-66.86%
ROE(3y)-61.66%
ROE(5y)-80.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.76%
GM growth 5Y29.76%
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.29
Quick Ratio 4.29
Altman-Z -3.16
F-Score2
WACC9.98%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.42%
EPS Next Y-25%
EPS Next 2Y-13.39%
EPS Next 3Y-25.99%
EPS Next 5Y-21.62%
Revenue 1Y (TTM)-7.69%
Revenue growth 3Y0.99%
Revenue growth 5Y12.51%
Sales Q2Q%-0.17%
Revenue Next Year0%
Revenue Next 2Y0%
Revenue Next 3Y0%
Revenue Next 5Y0%
EBIT growth 1Y-22.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.9%
OCF growth 3YN/A
OCF growth 5YN/A